BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for enGene Holdings Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-29 5:12 pm Sale | 2025-01-27 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND L P | 945,402 1.800% | -2,106,037 (-69.02%) | Filing |
| 2025-01-29 5:09 pm Sale | 2024-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND L P | 3,051,439 5.900% | -145,000 (-4.54%) | Filing |
| 2024-02-22 4:45 pm Unchanged | 2024-02-20 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND L P | 3,196,439 7.200% | 0 (Unchanged) | Filing |
| 2023-11-13 4:45 pm Purchase | 2023-10-31 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND L P | 3,196,439 13.200% | 3,196,439 (New Position) | Filing |